Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
The company's pending vaccine approvals could help the stock continue its rise.
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
Overview
Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick pony by using its messenger ribonucleic acid (mRNA) platform to expand its business. Investors have noticed, and the pharmaceutical stock is up more than 100% so far this year.
Because Moderna is trading at a premium price-to-sales ratio relative to its current revenue, buying the stock now is essentially a bet that its upcoming clinical data and Food and Drug Administration (FDA) approvals will successfully unlock the commercial viability of its broader mRNA pipeline.
Details
Here are three reasons to buy Moderna stock.
Source
Originally published at www.fool.com.
